Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFFRON-301: Tislelizumab + Sitravatinib vs Docetaxel in Pre-treated NSCLC
NCT04921358Phase 3Terminated
- Sponsor
- BeiGene
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of sitravatinib in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Jul 2021; status: terminated.
02
Drugs
sitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04921358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921358.